Purpose. The performance of a weight-based dosing protocol for unfractionated heparin (UFH) infusions using antifactor Xa monitoring was evaluated. Methods. The first 50 patients to receive a UFH ...
Background: Unfractionated heparin (UFH) has been used clinically for 5 decades. Despite being a cornerstone of anticoagulation, UFH is limited by its unpredictable pharmacokinetic profile, which ...
This webinar will look at the principles of the assays available to monitor heparin. The most frequent assay that is used is the activated partial thromboplastin time (aPTT). This assay is readily ...
Baebies Receives FDA Breakthrough Device Designation for First Point-of-Care Heparin Monitoring Test
DURHAM, N.C., April 23, 2025 /PRNewswire/ -- Baebies has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Anti-Factor Xa test on the FINDER® platform ...
Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was ...
Ever since the introduction of the direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, laboratory staff and clinicians have been confronted with unique challenges in determining ...
Heparin (ball and stick structure) activates antithrombin-III (gray) to bind to and inhibit thrombin (purple). All this raises the questions: Just what is heparin? Where does it come from? What does ...
An automated chromogenic test called the INNOVANCE Anti-Xa assay is used to quantify the levels of rivaroxaban 1, apixaban, and edoxaban 1 in citrated human plasma, as well as the activity of ...
Low molecular weight heparin (LMWH) is an anticoagulant injected subcutaneously or intravenously and acts via activation of antithrombin III which in turn inactivates thrombin and factor Xa to produce ...
A new study has shown that COVID-19 patients admitted to the Intensive care unit may be resistant to the naturally occurring anticoagulant Heparin. The study titled, “Heparin resistance in COVID‑19 ...
Therapeutic-dose heparin appears to benefit noncritically-ill COVID-19 patients, but it does not reduce deaths or other adverse endpoints compared with usual-care thromboprophylaxis if it’s initiated ...
We evaluated two patients in whom heparin-induced thrombocytopenia developed after orthopedic surgery, with the delayed-onset type in Patient 1 and the spontaneous type in Patient 2 (Figure 1). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results